Upstream Bio (UPB) Competitors $25.46 -0.48 (-1.85%) (As of 11/15/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsInsider TradesSEC FilingsTrends UPB vs. RNA, BBIO, BHVN, CRNX, ALKS, RARE, TGTX, AXSM, OGN, and RYTMShould you be buying Upstream Bio stock or one of its competitors? The main competitors of Upstream Bio include Avidity Biosciences (RNA), BridgeBio Pharma (BBIO), Biohaven (BHVN), Crinetics Pharmaceuticals (CRNX), Alkermes (ALKS), Ultragenyx Pharmaceutical (RARE), TG Therapeutics (TGTX), Axsome Therapeutics (AXSM), Organon & Co. (OGN), and Rhythm Pharmaceuticals (RYTM). These companies are all part of the "pharmaceutical preparations" industry. Upstream Bio vs. Avidity Biosciences BridgeBio Pharma Biohaven Crinetics Pharmaceuticals Alkermes Ultragenyx Pharmaceutical TG Therapeutics Axsome Therapeutics Organon & Co. Rhythm Pharmaceuticals Avidity Biosciences (NASDAQ:RNA) and Upstream Bio (NASDAQ:UPB) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their community ranking, valuation, institutional ownership, risk, earnings, analyst recommendations, dividends, media sentiment and profitability. Is RNA or UPB more profitable? Upstream Bio has a net margin of 0.00% compared to Avidity Biosciences' net margin of -2,772.45%. Upstream Bio's return on equity of 0.00% beat Avidity Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets Avidity Biosciences-2,772.45% -27.66% -24.56% Upstream Bio N/A N/A N/A Do analysts prefer RNA or UPB? Avidity Biosciences currently has a consensus target price of $63.22, suggesting a potential upside of 49.89%. Upstream Bio has a consensus target price of $56.50, suggesting a potential upside of 121.92%. Given Upstream Bio's higher probable upside, analysts clearly believe Upstream Bio is more favorable than Avidity Biosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Avidity Biosciences 0 Sell rating(s) 0 Hold rating(s) 9 Buy rating(s) 0 Strong Buy rating(s) 3.00Upstream Bio 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has preferable valuation and earnings, RNA or UPB? Upstream Bio has lower revenue, but higher earnings than Avidity Biosciences. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAvidity Biosciences$9.56M526.41-$212.22M-$2.88-14.65Upstream BioN/AN/AN/AN/AN/A Does the MarketBeat Community believe in RNA or UPB? Avidity Biosciences received 150 more outperform votes than Upstream Bio when rated by MarketBeat users. However, 100.00% of users gave Upstream Bio an outperform vote while only 67.25% of users gave Avidity Biosciences an outperform vote. CompanyUnderperformOutperformAvidity BiosciencesOutperform Votes15467.25% Underperform Votes7532.75% Upstream BioOutperform Votes4100.00% Underperform VotesNo Votes Does the media refer more to RNA or UPB? In the previous week, Avidity Biosciences had 13 more articles in the media than Upstream Bio. MarketBeat recorded 23 mentions for Avidity Biosciences and 10 mentions for Upstream Bio. Upstream Bio's average media sentiment score of 0.60 beat Avidity Biosciences' score of 0.55 indicating that Upstream Bio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Avidity Biosciences 6 Very Positive mention(s) 5 Positive mention(s) 9 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Upstream Bio 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryUpstream Bio beats Avidity Biosciences on 6 of the 10 factors compared between the two stocks. Ad Insiders ExposedHas Trump Finally Gone Too Far?Lately, there's been a lot of buzz around a secret loophole executive insiders are using to make millions buying and selling their own stocks. It's so powerful ... so profitable ... that most people immediately assume this is just another example of Trump doing what's best for business executives. But surprisingly, this loophole has been on the books for many years and executives have been using it to make HUNDREDS of millions of dollars. And here's the good news.Register For The Webinar To Discover Get Upstream Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for UPB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart UPB vs. The Competition Export to ExcelMetricUpstream BioPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.36B$6.52B$5.15B$8.74BDividend YieldN/A8.16%5.18%4.08%P/E RatioN/A4.8866.3713.55Price / SalesN/A376.691,276.8487.67Price / CashN/A51.2039.7035.24Price / BookN/A9.686.475.93Net IncomeN/A$154.43M$119.73M$225.73M7 Day Performance-2.75%-9.46%-5.13%-1.34%1 Month Performance7.88%-7.27%-2.71%1.15%1 Year PerformanceN/A28.13%31.08%24.02% Upstream Bio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)UPBUpstream Bio2.6688 of 5 stars$25.46-1.9%$56.50+121.9%N/A$1.36BN/A0.0038Quiet Period ExpirationRNAAvidity Biosciences2.5235 of 5 stars$47.36+1.4%N/A+611.3%$5.20B$9.56M-16.44190Analyst ForecastAnalyst RevisionNews CoverageBBIOBridgeBio Pharma4.608 of 5 stars$27.44+1.3%N/A-17.8%$5.16B$219.12M-10.43400Analyst ForecastAnalyst RevisionNews CoverageBHVNBiohaven3.811 of 5 stars$52.66-1.5%N/A+49.6%$4.98B$462.51M-5.76239Earnings ReportAnalyst ForecastNews CoverageCRNXCrinetics Pharmaceuticals3.5574 of 5 stars$61.21+0.9%N/A+93.1%$4.90B$1.39M-16.19210Earnings ReportAnalyst ForecastShort Interest ↑Analyst RevisionNews CoverageALKSAlkermes4.7266 of 5 stars$29.64+2.7%N/A+20.6%$4.80B$1.66B15.202,100Analyst ForecastInsider SellingRAREUltragenyx Pharmaceutical4.6312 of 5 stars$51.12+1.5%N/A+14.9%$4.72B$434.25M-7.901,276Analyst ForecastTGTXTG Therapeutics4.6168 of 5 stars$29.83+3.5%N/A+162.3%$4.62B$233.66M-298.27290Insider SellingAXSMAxsome Therapeutics4.6777 of 5 stars$90.16+0.1%N/A+56.0%$4.28B$291.49M-13.85589Earnings ReportAnalyst ForecastAnalyst RevisionNews CoverageOGNOrganon & Co.4.7935 of 5 stars$16.24+1.2%N/A+37.3%$4.18B$6.41B3.2210,000Ex-DividendNews CoveragePositive NewsRYTMRhythm Pharmaceuticals3.779 of 5 stars$67.66+0.5%N/A+73.2%$4.16B$77.43M-15.63140Insider Selling Related Companies and Tools Related Companies RNA Alternatives BBIO Alternatives BHVN Alternatives CRNX Alternatives ALKS Alternatives RARE Alternatives TGTX Alternatives AXSM Alternatives OGN Alternatives RYTM Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:UPB) was last updated on 11/17/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredThere is a little known company that is changing warfareWith geo - political instability around the world investors are flocking to defense contract stocks. There...Reticulate | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Upstream Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Upstream Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
